AZN
AstraZeneca PLC
AstraZeneca PLC historical holders
total: 4
Sanders Capital AstraZeneca PLC transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Reduced:
- 1
- Held since:
- 2026 Q1
- Held for:
- 2 quarters
- Latest activity:
- 2026 Q2
Lewis Sanders has been an institutional investor in AstraZeneca PLC (AZN) since 2026 Q1. According to 2026 Q2 report, Lewis Sanders holds 6,986,830 shares with a market value of roughly $1.32B representing 1.33% of their equity portfolio. The fund/company first acquired AZN in 2026 Q1, initially purchasing about 7.07M shares. Since the initial investment, Sanders Capital has made 1 more transaction in this position.
Does Lewis Sanders still hold AZN?
Yes, Lewis Sanders continues to hold AstraZeneca PLC (AZN). According to their 2026 Q2 report, they maintain a position of 6,986,830 shares valued at approximately $1.32B, representing 1.33% of their equity portfolio.
When did Lewis Sanders first invest in AZN?
Lewis Sanders first invested in AstraZeneca PLC (AZN) in 2026 Q1 at the reported quarter-end price of $197.22 per share, acquiring 7,065,628 shares in their initial purchase.
What is Lewis Sanders's average cost basis for AZN?
Based on historical transaction data, Lewis Sanders's estimated cost basis for AstraZeneca PLC (AZN) is approximately $197.22 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $197.22
- Weighted AVG sell price:
- $189.62
AZN transactions history by Sanders Capital
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
1.33%
|
6,986,830
|
$189.62
|
$1,324,842,705
|
-1.12% (-78,798)
|
-0.02%
|
|
2026 Q1
|
1.66%
|
7,065,628
|
$197.22
|
$1,393,483,154
|
new
|
+1.66%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.